Sponsors (4)
The bill leverages U.S.–Israel research, training, and regulatory cooperation to speed health innovation and improve care delivery, but it raises trade-offs around taxpayer cost, data privacy, equitable access, and concentrating partnerships with a single foreign country.
Researchers, biotech companies, and small business partners gain dedicated funding and coordinated U.S.–Israel R&D programs that accelerate development of new treatments and diagnostics.
Patients and health systems can see improved care delivery, interoperability, and greater use of telemedicine through shared best practices and technology exchanges between U.S. and Israeli hospitals.
U.S. healthcare and biomanufacturing workforces benefit from expanded training and exchange programs that build domestic skills and support manufacturing capacity.
Patients, especially low-income individuals, could face higher prices or reduced affordability if the program prioritizes market access and strong IP protection that favor private firms.
Sharing health data with a foreign government raises privacy and security risks for patients and health systems if safeguards and governance are insufficient.
Focusing resources and opportunities on collaboration with a single foreign country (Israel) could skew research and partnership opportunities away from broader global or domestic collaborations.
Based on analysis of 2 sections of legislative text.
Authorizes a program (up to $8M/year FY2026–2030) for HHS-led coordination of U.S.–Israel collaboration on medical R&D, regulatory alignment, telehealth, manufacturing, and workforce training.
Introduced January 23, 2025 by Vernon G. Buchanan · Last progress January 23, 2025
Requires the Secretary of Health and Human Services, working with Commerce, CMS technology leadership, and the FDA, to run a program to promote U.S.–Israel cooperation on medical product and service development. The program can support joint R&D, start‑up and innovation ecosystems, regulatory alignment and IP protection, telemedicine and digital health, disease prevention efforts, manufacturing of biological products, and workforce training, and may create a U.S.-based joint collaboration center; funding of $8 million per year is authorized for FY2026–FY2030, and implementation must begin within 6 months of enactment, subject to appropriations.